BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to ...

Lilly declined to provide sales or growth data for LillyDirect. But Zepbound paid for by patients outside of insurance holds potential to drive significant growth. In fact, according to Lilly ...

This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn't look like much ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

The collaboration connects Noom users with Eli Lilly’s pharmacy provider, GiftHealth, to facilitate access to Zepbound single-dose vials for individuals with a prescription, according to a March ...

The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management. Due to this ...